1
|
Matsumoto Y, Matsuya Y, Nagai K, Amagase K, Saeki K, Matsumoto K, Yokomizo T, Kato S. Leukotriene B 4 Receptor Type 2 Accelerates the Healing of Intestinal Lesions by Promoting Epithelial Cell Proliferation. J Pharmacol Exp Ther 2020; 373:1-9. [PMID: 31941716 DOI: 10.1124/jpet.119.263145] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2019] [Accepted: 01/02/2020] [Indexed: 12/19/2022] Open
Abstract
Leukotriene B4 receptor type 2 (BLT2) is a low-affinity leukotriene B4 receptor that is highly expressed in intestinal epithelial cells. Previous studies demonstrated the protective role of BLT2 in experimentally induced colitis. However, its role in intestinal lesion repair is not fully understood. We investigated the role of BLT2 in the healing of indomethacin-induced intestinal lesions in mice. There was no significant different between wild-type (WT) and BLT2-deficient (BLT2KO) mice in terms of the development of indomethacin-induced intestinal lesions. However, healing of these lesions was significantly impaired in BLT2KO mice compared with WT mice. In contrast, transgenic mice with intestinal epithelium-specific BLT2 overexpression presented with superior ileal lesion healing relative to WT mice. An immunohistochemical study showed that the number of Ki-67-proliferative cells was markedly increased during the healing of intestinal lesions in WT mice but significantly attenuated in BLT2KO mice. Exposure of cultured mouse intestinal epithelial cells to CAY10583, a BLT2 agonist, promoted wound healing and cell proliferation in a concentration-dependent manner. Nevertheless, these responses were abolished under serum-free conditions. The CAY10583-induced proliferative effect was also negated by Go6983, a protein kinase C (PKC) inhibitor, U-73122, a phospholipase C (PLC) inhibitor, LY255283, a BLT2 antagonist, and pertussis toxin that inhibits G protein-coupled receptor signaling via Gi/o proteins. Thus, BLT2 plays an important role in intestinal wound repair. Moreover, this effect is mediated by the promotion of epithelial cell proliferation via the Gi/o protein-dependent and PLC/PKC signaling pathways. The BLT2 agonists are potential therapeutic agents for the treatment of intestinal lesions. SIGNIFICANCE STATEMENT: The healing of indomethacin-induced Crohn's disease-like intestinal lesions was impaired in mice deficient in low-affinity leukotriene B4 receptor type 2 (BLT2). They presented with reduced epithelial cell proliferation during the healing. In contrast, healing was promoted in mice overexpressing intestinal epithelial BLT2. In cultured intestinal epithelial cells, the BLT2 agonist CAY10583 substantially accelerated wound repair by enhancing cell proliferation rather than migration. Thus, BLT2 plays an important role in the intestinal lesions via acceleration of epithelial cell proliferation.
Collapse
Affiliation(s)
- Yui Matsumoto
- Division of Pathological Sciences, Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Kyoto, Japan (Yui.M, Yuk.M., K.N., K.A., K.M., S.K.); Laboratory of Pharmacology and Pharmacotherapy, College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan (K.A.); and Department of Biochemistry, Juntendo University Graduate School of Medicine, Tokyo, Japan (K.S., T.Y.)
| | - Yukiko Matsuya
- Division of Pathological Sciences, Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Kyoto, Japan (Yui.M, Yuk.M., K.N., K.A., K.M., S.K.); Laboratory of Pharmacology and Pharmacotherapy, College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan (K.A.); and Department of Biochemistry, Juntendo University Graduate School of Medicine, Tokyo, Japan (K.S., T.Y.)
| | - Kano Nagai
- Division of Pathological Sciences, Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Kyoto, Japan (Yui.M, Yuk.M., K.N., K.A., K.M., S.K.); Laboratory of Pharmacology and Pharmacotherapy, College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan (K.A.); and Department of Biochemistry, Juntendo University Graduate School of Medicine, Tokyo, Japan (K.S., T.Y.)
| | - Kikuko Amagase
- Division of Pathological Sciences, Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Kyoto, Japan (Yui.M, Yuk.M., K.N., K.A., K.M., S.K.); Laboratory of Pharmacology and Pharmacotherapy, College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan (K.A.); and Department of Biochemistry, Juntendo University Graduate School of Medicine, Tokyo, Japan (K.S., T.Y.)
| | - Kazuko Saeki
- Division of Pathological Sciences, Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Kyoto, Japan (Yui.M, Yuk.M., K.N., K.A., K.M., S.K.); Laboratory of Pharmacology and Pharmacotherapy, College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan (K.A.); and Department of Biochemistry, Juntendo University Graduate School of Medicine, Tokyo, Japan (K.S., T.Y.)
| | - Kenjiro Matsumoto
- Division of Pathological Sciences, Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Kyoto, Japan (Yui.M, Yuk.M., K.N., K.A., K.M., S.K.); Laboratory of Pharmacology and Pharmacotherapy, College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan (K.A.); and Department of Biochemistry, Juntendo University Graduate School of Medicine, Tokyo, Japan (K.S., T.Y.)
| | - Takehiko Yokomizo
- Division of Pathological Sciences, Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Kyoto, Japan (Yui.M, Yuk.M., K.N., K.A., K.M., S.K.); Laboratory of Pharmacology and Pharmacotherapy, College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan (K.A.); and Department of Biochemistry, Juntendo University Graduate School of Medicine, Tokyo, Japan (K.S., T.Y.)
| | - Shinichi Kato
- Division of Pathological Sciences, Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Kyoto, Japan (Yui.M, Yuk.M., K.N., K.A., K.M., S.K.); Laboratory of Pharmacology and Pharmacotherapy, College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan (K.A.); and Department of Biochemistry, Juntendo University Graduate School of Medicine, Tokyo, Japan (K.S., T.Y.)
| |
Collapse
|
2
|
Affiliation(s)
- Tanya Sezin
- Department of Dermatology, Allergy, and Venereology, University of Lübeck, DE-23538 Lübeck, Germany
| | | | | |
Collapse
|
3
|
Ahluwalia N, Lin AY, Tager AM, Pruitt IE, Anderson TJT, Kristo F, Shen D, Cruz AR, Aikawa M, Luster AD, Gerszten RE. Inhibited aortic aneurysm formation in BLT1-deficient mice. J Immunol 2007; 179:691-7. [PMID: 17579092 DOI: 10.4049/jimmunol.179.1.691] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Leukotriene B(4) is a proinflammatory lipid mediator generated by the enzymes 5-lipoxygenase and leukotriene A(4) hydrolase. Leukotriene B(4) signals primarily through its high-affinity G protein-coupled receptor, BLT1, which is highly expressed on specific leukocyte subsets. Recent genetic studies in humans as well as knockout studies in mice have implicated the leukotriene synthesis pathway in several vascular pathologies. In this study, we tested the hypothesis that BLT1 is necessary for abdominal aortic aneurysm (AAA) formation, a major complication of atherosclerotic vascular disease. Chow-fed Apoe(-/-) and Apoe(-/-)/Blt1(-/-) mice were treated with a 4-wk infusion of angiotensin II (1000 ng/min/kg) beginning at 20 wk of age, in a well-established murine AAA model. We found a reduced incidence of AAA formation as well as concordant reductions in the maximum suprarenal/infrarenal diameter and total suprarenal/infrarenal area in the angiotensin II-treated Apoe(-/-)/Blt1(-/-) mice as compared with the Apoe(-/-) controls. Diminished AAA formation in BLT1-deficient mice was associated with significant reductions in mononuclear cell chemoattractants and leukocyte accumulation in the vessel wall, as well as striking reductions in the production of matrix metalloproteinases-2 and -9. Thus, we have shown that BLT1 contributes to the frequency and size of abdominal aortic aneurysms in mice and that BLT1 deletion in turn inhibits proinflammatory circuits and enzymes that modulate vessel wall integrity. These findings extend the role of BLT1 to a critical complication of vascular disease and underscore its potential as a target for intervention in modulating multiple pathologies related to atherosclerosis.
Collapse
MESH Headings
- Animals
- Aorta, Abdominal/enzymology
- Aorta, Abdominal/metabolism
- Aorta, Abdominal/pathology
- Aortic Aneurysm, Abdominal/genetics
- Aortic Aneurysm, Abdominal/metabolism
- Aortic Aneurysm, Abdominal/pathology
- Aortic Aneurysm, Abdominal/prevention & control
- Apolipoproteins E/deficiency
- Apolipoproteins E/genetics
- Cell Migration Inhibition
- Disease Models, Animal
- Humans
- Leukotriene B4/biosynthesis
- Leukotriene B4/metabolism
- Macrophages/immunology
- Macrophages/metabolism
- Macrophages/pathology
- Matrix Metalloproteinase 2/metabolism
- Matrix Metalloproteinase 9/metabolism
- Matrix Metalloproteinase Inhibitors
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Monocytes/enzymology
- Monocytes/metabolism
- Monocytes/pathology
- Receptors, Leukotriene B4/deficiency
- Receptors, Leukotriene B4/genetics
- Receptors, Leukotriene B4/physiology
- T-Lymphocytes/immunology
- T-Lymphocytes/pathology
Collapse
Affiliation(s)
- Neil Ahluwalia
- Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Charlestown, MA 02129, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol 2007; 178:3912-7. [PMID: 17339491 DOI: 10.4049/jimmunol.178.6.3912] [Citation(s) in RCA: 453] [Impact Index Per Article: 26.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Resolvin E1 (RvE1) is a potent anti-inflammatory and proresolving mediator derived from omega-3 eicosapentaenoic acid generated during the resolution phase of inflammation. RvE1 possesses a unique structure and counterregulatory actions that stop human polymorphonuclear leukocyte (PMN) transendothelial migration and PMN infiltration in several murine inflammatory models. To examine the mechanism(s) underlying anti-inflammatory actions on PMNs, we prepared [(3)H]RvE1 and characterized its interactions with human PMN. Results with membrane fractions of human PMN demonstrated specific binding with a K(d) of 48.3 nM. [(3)H]RvE1 specific binding to human PMN was displaced by leukotriene B(4) (LTB(4)) and LTB(4) receptor 1 (BLT1) antagonist U-75302, but not by chemerin peptide, a ligand specific for another RvE1 receptor ChemR23. Recombinant human BLT1 gave specific binding with [(3)H]RvE1 with a K(d) of 45 nM. RvE1 selectively inhibited adenylate cyclase with BLT1, but not with BLT2. In human PBMC, RvE1 partially induced calcium mobilization, and blocked subsequent stimulation by LTB(4). RvE1 also attenuated LTB(4)-induced NF-kappaB activation in BLT1-transfected cells. In vivo anti-inflammatory actions of RvE1 were sharply reduced in BLT1 knockout mice when given at low doses (100 ng i.v.) in peritonitis. In contrast, RvE1 at higher doses (1.0 mug i.v.) significantly reduced PMN infiltration in a BLT1-independent manner. These results indicate that RvE1 binds to BLT1 as a partial agonist, potentially serving as a local damper of BLT1 signals on leukocytes along with other receptors (e.g., ChemR23-mediated counterregulatory actions) to mediate the resolution of inflammation.
Collapse
Affiliation(s)
- Makoto Arita
- Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
| | | | | | | | | | | |
Collapse
|
5
|
Shao WH, Del Prete A, Bock CB, Haribabu B. Targeted Disruption of Leukotriene B4 Receptors BLT1 and BLT2: A Critical Role for BLT1 in Collagen-Induced Arthritis in Mice. J Immunol 2006; 176:6254-61. [PMID: 16670336 DOI: 10.4049/jimmunol.176.10.6254] [Citation(s) in RCA: 81] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Leukotriene B(4) mediates diverse inflammatory diseases through the G protein-coupled receptors BLT1 and BLT2. In this study, we developed mice deficient in BLT1 and BLT2 by simultaneous targeted disruption of these genes. The BLT1/BLT2 double-deficient mice developed normally and peritoneal exudate cells showed no detectable responses to leukotriene B(4) confirming the deletion of the BLT1/BLT2 locus. In a model of collagen-induced arthritis on the C57BL/6 background, the BLT1/BLT2(-/-) as well as the previously described BLT1(-/-) animals showed complete protection from disease development. The disease severity correlated well with histopathology, including loss of joint architecture, inflammatory cell infiltration, fibrosis, pannus formation, and bone erosion in joints of BLT1/BLT2(+/+) animals and a total absence of disease pathology in leukotriene receptor-deficient mice. Despite these differences, all immunized BLT1(-/-) and BLT1/BLT2(-/-) animals had similar serum levels of anti-collagen Abs relative to BLT1/BLT2(+/+) animals. Thus, BLT1 may be a useful target for therapies directed at treating inflammation associated with arthritis.
Collapse
MESH Headings
- Animals
- Arthritis, Experimental/genetics
- Arthritis, Experimental/metabolism
- Arthritis, Experimental/prevention & control
- Cell Line
- Gene Expression Regulation/immunology
- Leukotriene B4/metabolism
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Receptors, Leukotriene B4/deficiency
- Receptors, Leukotriene B4/genetics
- Receptors, Leukotriene B4/physiology
- Receptors, Purinergic P2/deficiency
- Receptors, Purinergic P2/genetics
- Receptors, Purinergic P2/physiology
Collapse
Affiliation(s)
- Wen-Hai Shao
- James Graham Brown Cancer Center, and Department of Microbiology and Immunology, University of Louisville Health Sciences Center, Louisville, KY 40202, USA
| | | | | | | |
Collapse
|
6
|
Taube C, Miyahara N, Ott V, Swanson B, Takeda K, Loader J, Shultz LD, Tager AM, Luster AD, Dakhama A, Gelfand EW. The leukotriene B4 receptor (BLT1) is required for effector CD8+ T cell-mediated, mast cell-dependent airway hyperresponsiveness. J Immunol 2006; 176:3157-64. [PMID: 16493075 DOI: 10.4049/jimmunol.176.5.3157] [Citation(s) in RCA: 82] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Studies in both humans and rodents have suggested that CD8+ T cells contribute to the development of airway hyperresponsiveness (AHR) and that leukotriene B4 (LTB4) is involved in the chemotaxis of effector CD8+ T cells (T(EFF)) to the lung by virtue of their expression of BLT1, the receptor for LTB4. In the present study, we used a mast cell-CD8-dependent model of AHR to further define the role of BLT1 in CD8+ T cell-mediated AHR. C57BL/6+/+ and CD8-deficient (CD8-/-) mice were passively sensitized with anti-OVA IgE and exposed to OVA via the airways. Following passive sensitization and allergen exposure, C57BL/6+/+ mice developed altered airway function, whereas passively sensitized and allergen-exposed CD8-/- mice failed to do so. CD8-/- mice reconstituted with CD8+ T(EFF) developed AHR in response to challenge. In contrast, CD8-/- mice reconstituted with BLT1-deficient effector CD8+ T cells did not develop AHR. The induction of increased airway responsiveness following transfer of CD8+ T(EFF) or in wild-type mice could be blocked by administration of an LTB4 receptor antagonist confirming the role of BLT1 in CD8+ T cell-mediated AHR. Together, these data define the important role for mast cells and the LTB4-BLT1 pathway in the development of CD8+ T cell-mediated allergic responses in the lung.
Collapse
MESH Headings
- Adoptive Transfer
- Animals
- Bronchial Hyperreactivity/genetics
- Bronchial Hyperreactivity/immunology
- Bronchial Hyperreactivity/metabolism
- CD8-Positive T-Lymphocytes/immunology
- CD8-Positive T-Lymphocytes/transplantation
- Female
- Interleukin-13/physiology
- Leukotriene B4/metabolism
- Mast Cells/immunology
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Mice, Knockout
- Mice, Transgenic
- Receptors, Antigen, T-Cell/genetics
- Receptors, IgE/biosynthesis
- Receptors, IgE/deficiency
- Receptors, IgE/genetics
- Receptors, Leukotriene B4/deficiency
- Receptors, Leukotriene B4/genetics
- Receptors, Leukotriene B4/physiology
- Receptors, Purinergic P2/deficiency
- Receptors, Purinergic P2/genetics
- Receptors, Purinergic P2/physiology
Collapse
Affiliation(s)
- Christian Taube
- Division of Cell Biology, Department of Pediatrics, National Jewish Medical and Research Center, Denver, CO 80206, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Terawaki K, Yokomizo T, Nagase T, Toda A, Taniguchi M, Hashizume K, Yagi T, Shimizu T. Absence of leukotriene B4 receptor 1 confers resistance to airway hyperresponsiveness and Th2-type immune responses. J Immunol 2005; 175:4217-25. [PMID: 16177061 DOI: 10.4049/jimmunol.175.7.4217] [Citation(s) in RCA: 140] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Bronchial asthma is an increasingly common disorder that remains poorly understood and difficult to manage. The disease is characterized by airway hyperresponsiveness, chronic inflammation, and mucus overproduction. Based on the finding that leukotriene B4 receptor 1 (BLT1) is expressed highly in Th2 lymphocytes, we analyzed the roles of BLT1 using an OVA-induced bronchial asthma model. BLT1-null mice did not develop airway hyperresponsiveness, eosinophilic inflammation, and hyperplasia of goblet cells. Attenuated symptoms were accompanied by reduced IgE production, and accumulation of IL-5 and IL-13 in bronchoalveolar lavage fluid, suggesting attenuated Th2-type immune response in BLT1-null mice. Peribronchial lymph node cells of sensitized BLT1-null mice showed much attenuated proliferation and production of Th2 cytokines upon re-stimulation with Ag in vitro. Thus, LTB4-BLT1 axis is required for the development of Th2-type immune response, and blockade of LTB4 functions through BLT1 would be novel and useful in the effort to ameliorate bronchial asthma and related Th2-biased immune disorders.
Collapse
Affiliation(s)
- Kan Terawaki
- Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Tokyo, Japan
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Medoff BD, Seung E, Wain JC, Means TK, Campanella GSV, Islam SA, Thomas SY, Ginns LC, Grabie N, Lichtman AH, Tager AM, Luster AD. BLT1-mediated T cell trafficking is critical for rejection and obliterative bronchiolitis after lung transplantation. ACTA ACUST UNITED AC 2005; 202:97-110. [PMID: 15998790 PMCID: PMC2212891 DOI: 10.1084/jem.20042481] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Leukotriene B4 is a lipid mediator that recently has been shown to have potent chemotactic activity for effector T lymphocytes mediated through its receptor, BLT1. Here, we developed a novel murine model of acute lung rejection to demonstrate that BLT1 controls effector CD8+ T cell trafficking into the lung and that disruption of BLT1 signaling in CD8+ T cells reduces lung inflammation and mortality in the model. In addition, we used BLT1-deficient mice and a BLT1 antagonist in two tracheal transplant models of lung transplantation to demonstrate the importance of BLT1 for the recruitment of T cells into tracheal allografts. We also show that BLT1-mediated CD8+ T cell recruitment plays an important role in the development of airway fibroproliferation and obliteration. Finally, in human studies of lung transplant recipients, we found that BLT1 is up-regulated on T lymphocytes isolated from the airways of patients with obliterative bronchiolitis. These data demonstrate that BLT1 contributes to the development of lung rejection and obliterative bronchiolitis by mediating effector T lymphocyte trafficking into the lung. This is the first report that describes a pathologic role for BLT1-mediated T lymphocyte recruitment in disease and identifies BLT1 as a potential therapeutic target after lung transplantation.
Collapse
Affiliation(s)
- Benjamin D Medoff
- Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Medoff BD, Tager AM, Jackobek R, Means TK, Wang L, Luster AD. Antibody-antigen interaction in the airway drives early granulocyte recruitment through BLT1. Am J Physiol Lung Cell Mol Physiol 2005; 290:L170-8. [PMID: 16126787 DOI: 10.1152/ajplung.00212.2005] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
Antibody-antigen interactions in the airway initiate inflammation in acute asthma exacerbations. This inflammatory response is characterized by the recruitment of granulocytes into the airways. In murine models of asthma, granulocyte recruitment into the lung contributes to the development of airway hyperresponsiveness (AHR), mucus production, and airway remodeling. Leukotriene B4 is a mediator released following antigen challenge that has chemotactic activity for granulocytes, mediated through its receptor, BLT1. We investigated the role of BLT1 in granulocyte recruitment following antigen challenge. Wild-type mice and BLT1-/- mice were sensitized and challenged with ovalbumin (OVA) to induce acute allergic airway inflammation. In addition, to explore the relevance to antibody-antigen interactions, we injected OVA bound to anti-OVA IgG1 or anti-OVA IgE intratracheally into naïve wild-type and BLT1-/- mice. Cell composition of the lungs, cytokine levels, histology, and AHR were determined. After sensitization and challenge with ovalbumin, there was significantly reduced neutrophil and eosinophil recruitment into the airways of BLT1-/- mice compared with wild-type animals after one or two daily antigen challenges, but this difference was not seen after three or four daily antigen challenges. Mucus production and AHR were not affected. Intratracheal injection of OVA bound to IgG1 or IgE induced neutrophil recruitment into the airways in wild-type mice but not in the BLT1-/- mice. We conclude that BLT1 mediates early recruitment of granulocytes into the airway in response to antigen-antibody interactions in a murine model of acute asthma.
Collapse
Affiliation(s)
- Benjamin D Medoff
- Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Charlestown, MA 02129, USA
| | | | | | | | | | | |
Collapse
|
10
|
Allendorf DJ, Yan J, Ross GD, Hansen RD, Baran JT, Subbarao K, Wang L, Haribabu B. C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and beta-glucan. J Immunol 2005; 174:7050-6. [PMID: 15905548 DOI: 10.4049/jimmunol.174.11.7050] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Intravenous and orally administered beta-glucans promote tumor regression and survival by priming granulocyte and macrophage C receptor 3 (CR3, iC3bR and CD11b/CD18) to trigger the cytotoxicity of tumor cells opsonized with iC3b via anti-tumor Abs. Despite evidence for priming of macrophage CR3 by oral beta-glucan in vivo, the current study in C57BL/6 and BALB/c mice showed that granulocytes were the essential killer cells in mAb- and oral beta-glucan-mediated tumor regression, because responses were absent in granulocyte-depleted mice. Among granulocytes, neutrophils were the major effector cells, because tumor regression did not occur when C5a-dependent chemotaxis was blocked with a C5aR antagonist, whereas tumor regression was normal in C3aR(-/-) mice. Neutrophil recruitment by C5a in vivo required amplification via leukotriene B(4), because both C5a-mediated leukocyte recruitment into the peritoneal cavity and tumor regression were suppressed in leukotriene B(4)R-deficient (BLT-1(-/-)) mice.
Collapse
MESH Headings
- Administration, Oral
- Animals
- Antibodies, Monoclonal/therapeutic use
- Cell Line, Tumor
- Chemotaxis, Leukocyte/genetics
- Chemotaxis, Leukocyte/immunology
- Complement C3a/physiology
- Complement C5a/physiology
- Granulocytes/cytology
- Granulocytes/immunology
- Killer Cells, Natural/cytology
- Killer Cells, Natural/immunology
- Leukotriene B4/physiology
- Lymphoma/immunology
- Lymphoma/pathology
- Lymphoma/therapy
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Mice, Knockout
- Neutrophil Infiltration/genetics
- Neutrophil Infiltration/immunology
- Receptors, Leukotriene B4/deficiency
- Receptors, Leukotriene B4/genetics
- Receptors, Leukotriene B4/physiology
- beta-Glucans/administration & dosage
- beta-Glucans/therapeutic use
Collapse
Affiliation(s)
- Daniel J Allendorf
- Tumor Immunobiology Program of the James Graham Brown Cancer Center, University of Louisville School of Medicine, KY 40202, USA
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Heller EA, Liu E, Tager AM, Sinha S, Roberts JD, Koehn SL, Libby P, Aikawa ER, Chen JQ, Huang P, Freeman MW, Moore KJ, Luster AD, Gerszten RE. Inhibition of Atherogenesis in BLT1-Deficient Mice Reveals a Role for LTB4 and BLT1 in Smooth Muscle Cell Recruitment. Circulation 2005; 112:578-86. [PMID: 16043658 DOI: 10.1161/circulationaha.105.545616] [Citation(s) in RCA: 107] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Background—
It is known that 5-lipoxygenase and its product, leukotriene B4 (LTB
4
), are highly expressed in several human pathologies, including atherosclerotic plaque. LTB
4
signals primarily through its high-affinity G protein-coupled receptor BLT1, which is expressed on specific leukocyte subsets. BLT1 receptor expression and function on other atheroma-associated cell types is unknown.
Methods and Results—
To directly assess the role of the LTB
4
-BLT1 pathway in atherogenesis, we bred BLT1
−/−
mice into the atherosclerosis-susceptible apoE
−/−
strain. Compound-deficient apoE
−/−
/Blt1
−/−
mice fed a Western-type diet had a marked reduction in plaque formation compared with apoE
−/−
controls. Immunohistochemical analysis of atherosclerotic lesions in compound-deficient mice revealed a striking decrease in smooth muscle cells (SMCs) and significant decreases in macrophages and T cells. We report here novel evidence of the expression and function of BLT1 on vascular SMCs. LTB
4
triggered SMC chemotaxis, which was pertussis toxin sensitive in Blt1
+/+
SMCs and absent in Blt1
−/−
cells, suggesting that BLT1 was the dominant receptor mediating effector functions through a G protein-coupled signaling pathway. Furthermore, BLT1 colocalized with SMCs in human atherosclerotic lesions.
Conclusions—
These new findings extend the role of inducible BLT1 to nonleukocyte populations and suggest an important target for intervention to modulate the response to vascular injury.
Collapse
MESH Headings
- Animals
- Apolipoproteins E/physiology
- Atherosclerosis/etiology
- Atherosclerosis/prevention & control
- Cell Movement
- Immunohistochemistry
- Leukotriene B4/pharmacology
- Mice
- Mice, Inbred C57BL
- Muscle, Smooth, Vascular/cytology
- Myocytes, Smooth Muscle/cytology
- Receptors, CCR2
- Receptors, Chemokine/physiology
- Receptors, Leukotriene B4/deficiency
- Receptors, Leukotriene B4/physiology
- Receptors, Purinergic P2/deficiency
- Receptors, Purinergic P2/physiology
- Signal Transduction
Collapse
Affiliation(s)
- Eric A Heller
- Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, East-8307, 149 13th St, Charlestown, MA 02129, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Miyahara N, Takeda K, Miyahara S, Matsubara S, Koya T, Joetham A, Krishnan E, Dakhama A, Haribabu B, Gelfand EW. Requirement for leukotriene B4 receptor 1 in allergen-induced airway hyperresponsiveness. Am J Respir Crit Care Med 2005; 172:161-7. [PMID: 15849325 PMCID: PMC2718465 DOI: 10.1164/rccm.200502-205oc] [Citation(s) in RCA: 89] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
RATIONALE Leukotriene B4 (LTB4) is a rapidly synthesized, early leukocyte chemoattractant that signals via its cell surface receptor, leukotriene B4 receptor 1 (BLT1), to attract and activate leukocytes during inflammation. A role for the LTB4-BLT1 pathway in allergen-induced airway hyperresponsiveness and inflammation is not well defined. OBJECTIVES To define the role of the LTB4 receptor (BLT1) in the development of airway inflammation and altered airway function. METHODS BLT1-deficient (BLT1 -/-) mice and wild-type mice were sensitized to ovalbumin by intraperitoneal injection and then challenged with ovalbumin via the airways. Airway responsiveness to inhaled methacholine, bronchoalveolar lavage fluid cell composition and cytokine levels, and lung inflammation and goblet cell hyperplasia were assessed. RESULTS Compared with wild-type mice, BLT1 -/- mice developed significantly lower airway responsiveness to inhaled methacholine, lower goblet cell hyperplasia in the airways, and decreased interleukin (IL)-13 production both in vivo, in the bronchoalveolar lavage fluid, and in vitro, after antigen stimulation of lung cells in culture. Intracellular cytokine staining of lung cells revealed that bronchoalveolar lavage IL-13 levels and numbers of IL-13(+)/CD4+ and IL-13(+)/CD8+ T cells were also reduced in BLT1 -/- mice. Reconstitution of sensitized and challenged BLT1 -/- mice with allergen-sensitized BLT1 +/+ T cells fully restored the development of airway hyperresponsiveness. In contrast, transfer of naive T cells failed to do so. CONCLUSION These data suggest that BLT1 expression on primed T cells is required for the full development of airway hyperresponsiveness, which appears to be associated with IL-13 production in these cells.
Collapse
Affiliation(s)
- Nobuaki Miyahara
- National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Subbarao K, Jala VR, Mathis S, Suttles J, Zacharias W, Ahamed J, Ali H, Tseng MT, Haribabu B. Role of Leukotriene B
4
Receptors in the Development of Atherosclerosis: Potential Mechanisms. Arterioscler Thromb Vasc Biol 2004; 24:369-75. [PMID: 14656734 DOI: 10.1161/01.atv.0000110503.16605.15] [Citation(s) in RCA: 168] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective—
Leukotriene B
4
(LTB
4
), a potent leukocyte chemoattractant, is known to promote several inflammatory diseases, including atherosclerosis. We sought to determine mechanisms through which LTB
4
modulates atherosclerosis in cell lines expressing LTB
4
receptors, BLT-1, and in mice deficient in BLT-1 as well as macrophage cell lines derived from BLT-1
+/+
and BLT-1
−/−
mice.
Methods and Results—
Analysis of global changes in gene expression induced by LTB
4
in rat basophilic leukemia cells (RBL-2H3) expressing the human BLT-1 showed highest-fold increase in expression of fatty acid translocase/CD36 and the chemokine MCP1/JE/CCL2 , which are critical in atherogenesis. To determine the importance of BLT-1 in atherogenesis, we crossed BLT-1-null mice with apolipoprotein (apo)-E-deficient mice, which develop severe atherosclerosis. Deletion of BLT-1 significantly reduced the lesion formation in apo-E
−/−
mice only during initiating stages (4 and 8 weeks) but had no effect on the lesion size in mice fed atherogenic diet for 19 weeks. Macrophage cell lines from BLT-1-deficient mice expressed the low-affinity LTB
4
receptor, BLT-2, and exhibited chemotaxis to LTB
4
.
Conclusions—
The effects of LTB
4
in atherosclerosis are likely mediated through the high-affinity BLT-1 and the low-affinity BLT-2 receptors. LTB
4
promotes atherosclerosis by chemo-attracting monocytes, by providing an amplification loop of monocyte chemotaxis via CCL2 production, and by converting monocytes to foam cells by enhanced expression of CD36 and fatty acid accumulation.
Collapse
MESH Headings
- Animals
- Apolipoproteins E/deficiency
- Apolipoproteins E/physiology
- Arteriosclerosis/etiology
- Arteriosclerosis/genetics
- Cells, Cultured
- Chemotaxis/physiology
- Crosses, Genetic
- Female
- Gene Expression Profiling/methods
- Gene Expression Regulation/physiology
- Humans
- Leukotriene B4/physiology
- Macrophages/chemistry
- Macrophages/metabolism
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Mutant Strains
- Oligonucleotide Array Sequence Analysis/methods
- RNA, Messenger/metabolism
- Rats
- Receptors, Leukotriene/biosynthesis
- Receptors, Leukotriene/physiology
- Receptors, Leukotriene B4/biosynthesis
- Receptors, Leukotriene B4/deficiency
- Receptors, Leukotriene B4/physiology
Collapse
Affiliation(s)
- Krishnaprasad Subbarao
- James Graham Brown Cancer Center, University of Louisville Health Sciences, Louisville, KY 40202, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Yokomizo T. [Metabolism and receptors of leukotriene B4]. Seikagaku 2002; 74:1139-47. [PMID: 12402454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/27/2023]
Affiliation(s)
- Takehiko Yokomizo
- Department of Biochemistry and Molecular Biology, PRESTO of JST, Faculty of Medicine, University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033
| |
Collapse
|